前肿瘤反应性T细胞的体外扩增Bryostatin 1/Ionomycin手段和共同的γ链细胞因子配方

为有效的协议

据报道，乳腺癌患者既存的免疫反应，对^他们的肿瘤1,2。然而，这种免疫反应，未能提供完整的保护，对发展或复发的乳腺癌。为了克服这个问题，通过增加肿瘤反应性T细胞的频率，过继免疫治疗已聘用。扩大肿瘤特异性T细胞已被用于多种协议。然而，这些协议限制的肿瘤抗原体外抗原特异性T细胞的活化使用。最近，常见的伽玛链细胞因子如IL - 2，IL - 7，IL - 15和IL - 21已单独或联合使用的抗肿瘤免疫反应的³的增强。不过，目前尚不清楚制定工作，为扩大肿瘤反应性T细胞的最佳。在这里，我们提出了一个从FVBN202在收养的T细胞治疗乳腺癌HER-2/neu的阳性乳腺癌的转基因小鼠模型的肿瘤反应性T细胞的选择性激活和扩张的协议。该协议包括bryostatin-1/ionomycin（B / I）和IL - 2激活T细胞，在16个小时的肿瘤抗原的情况下。 /我的激活模仿细胞内的信号，导致T细胞的活化蛋白激酶C活性和细胞内钙离子增加， ^分别为4。该协议具体激活肿瘤特异性T细胞，而造成不相关的T细胞。与IL - 7和IL - 15的B /我激活T细胞培养24小时，然后用IL - 2脉冲。 24小时后，T细胞被洗净，分割，并培养与IL - 7 + IL - 15增加4天。 前体外扩增的T细胞特异性肿瘤和抗肿瘤疗效是确定的。

为有效的协议

这项工作是由美国国立卫生研究院R01 CA104757格兰特（MH Manjili）的支持。我们非常感谢VCU梅西癌症中心的支持和英联邦基金会为癌症研究。

1. Goodell, V., Waisman, J., Salazar, L. G., de la Rosa, C., Link, J., Coveler, A. L., Childs, J. S., Fintak, P. A., Higgins, D. M., Disis, M. L. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther. 7, 449-454 (2008).
2. Disis, M. L., Knutson, K. L., Schiffman, K., Rinn, K., McNeel, D. G. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat. 62, 245-252 (2000).
3. Liu, S., Riley, J., Rosenberg, S., Parkhurst, M. Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy. J. Immunother. 29, 284-293 (2006).
4. Bear, H. D., Roberts, J., Cornell, D., Tombes, M. B., Kyle, B. Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial. Cancer Immunol Immunother. 5, 269-274 (2001).
5. Morales, J. K., Kmieciak, M., Graham, L., Feldmesser, M., Bear, H. D., Manjili, M. H. Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunol Immunother. 58, 941-953 (2009).
6. Cha, E., Graham, L., Manjili, M. H., Bear, H. D., Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo. Breast Cancer Res Treat. 89, 10578-10582 (2009).
7. Kmieciak, M., Morales, J. K., Morales, J., Bolesta, E., Grimes, M., Manjili, M. H. Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design. Cancer Immunol Immunother. 57, 1391-1398 (2008).
8. Stern, J. B., Smith, K. A. Interleukin-2 induction of T-cell G1 progression and c-myb expression. Science. 233, 203-206 (1986).
9. Kittipatarin, C., Khaled, A. R. ex vivo expansion of memory CD8 T cells from lymph nodes or spleen through in vitro culture with interleukin-7. J Immunol Methods. 344, 45-57 (2009).
10. Kokaji, A. I., Hockley, D. L., Kane, K. P. IL-15 transpresentation augments CD8+ T cell activation and is required for optimal recall responses by central memory CD8+ T cells. J Immunol. 180, 4391-4401 (2008).
11. Le, H. K., Graham, L., Miller, C. H., Kmieciak, M., Manjili, M. H., Bear, H. D. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunol Immunother. 58, 1565-1576 (2009).